Diabetic Eye Disease

Latest News

Image Credit: © Seventyfour - stock.adobe.com
Alimera completes recruitment for its NEW DAY study

May 25th 2023

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

This week in optometry: March 20-March 24
This week in optometry: March 20-March 24

March 25th 2023

Do diabetes, diabetic retinal disease contribute to macular degeneration?
Do diabetes, diabetic retinal disease contribute to macular degeneration?

March 21st 2023

row of syringes of aflibercept
Regeneron receives FDA acceptance, priority review of BLA for aflibercept 8 mg for wet AMD and DME

February 23rd 2023

Surprising findings from the DRCR Retina Network Protocol AA
Surprising findings from the DRCR Retina Network Protocol AA

January 23rd 2023

Video Series
Video Interviews
Podcasts
Dr. Kerry Gelb speaks with Dr. Jay M. Hainie in the second part of their discussion on diabetes of the eye!
Open Your Eyes with Dr Kerry Gelb featuring Dr. Jay Haynie in "diabetes of the eye"
Latest CME Events & Activities

Cases and Conversations™: New Treatment Strategies for nAMD & DME

07/28/2023

View More

Cases and Conversations™: New Treatment Strategies for nAMD & DME

07/28/2023

View More

Cases and Conversations™: New Treatment Strategies for nAMD & DME

07/28/2023

View More

Cases and Conversations™: New Treatment Strategies for nAMD & DME

07/28/2023

View More

Cases and Conversations™: New Treatment Strategies for nAMD & DME

07/28/2023

View More

Cases and Conversations™: New Treatment Strategies for nAMD & DME

07/28/2023

View More

Ophthalmology Consultations™: Keeping an Eye Out for MGD-Associated Dry Eye in Pre/Post-Op Patients – Improving Surgical Outcomes by Optimizing the Surface

View More

Community Practice Connections™: Inflammation & Pathogenesis in DME – Rethinking the Traditional Treatment Paradigm

View More

(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

Comprehensive Key Advances in Biosimilars for Retinal Diseases – Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Specialist

View More

(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

Cases & Conversations™: Inflammation & Pathogenesis in DME – Rethinking the Traditional Treatment Paradigm

View More

(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

View More

(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases

View More

(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases

View More

(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases

View More

(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases

View More

(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases

View More

(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases

View More

(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases

View More

(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases

View More

More News

Managing low vision in an aging population

Managing low vision in an aging population

Parres Wright, OD, FAAO
January 5th 2023

As Baby Boomers enter the at-risk age group for vision loss, optometrists must be ready to act.

Have a patient with diabetes? Get the whole story

Have a patient with diabetes? Get the whole story

A. Paul Chous, MA, OD, FAAO
November 24th 2022

Case history can give clues to a patient’s risk of developing diabetic eye disease.

FDA approves intravenous injection for delayed onset of stage 3 type 1 diabetes

FDA approves intravenous injection for delayed onset of stage 3 type 1 diabetes

Lynda Charters
November 18th 2022

Teplizumab may work by binding to certain immune system cells that attack insulin-producing cells and increase the proportion of cells that help moderate the immune response, thus delaying progression to stage 3 type 1 diabetes.

It’s not your grandparents’ anti-VEGF therapy

It’s not your grandparents’ anti-VEGF therapy

A. Paul Chous, MA, OD, FAAO
August 22nd 2022

New DME treatments aim to extend time between intravitreal injections.

NIH-funded clinical trial results support “step therapy” for DME treatment

NIH-funded clinical trial results support “step therapy” for DME treatment

Kassi Jackson, Editor
August 19th 2022

A recent clinical trial from the DRCR Retina Network examined a stepped regimen of anti-VEGF drugs bevacizumab and aflibercept.

PDR: public health considerations

PDR: public health considerations

Autumnn Wooten, OD;Angelina Tran, OD;Bhagya Segu, OD, MPH, FAAO
August 9th 2022

Proper screenings, treatment, management needed for this increasingly prevalent disease.

Case study: Patient presents with severe PDR history

Case study: Patient presents with severe PDR history

Autumnn Wooten, OD;Angelina Tran, OD;Bhagya Segu, OD, MPH, FAAO
August 8th 2022

The patient’s ocular history was significant for severe nonproliferative diabetic retinopathy (NPDR) in the right eye (OD) and mild NPDR in the left eye (OS), which had been diagnosed 4 years previously at his last eye exam.

2022 updates to ADA standards of care for patients with diabetes

2022 updates to ADA standards of care for patients with diabetes

A. Paul Chous, MA, OD, FAAO
May 30th 2022

The ADA now recommends an individualized approach at diagnosis of diabetes as well as for adults who do not have symptoms to be screened at age 35 years.

5 diabetes truisms that are (at least partially) false

5 diabetes truisms that are (at least partially) false

A. Paul Chous, MA, OD, FAAO
March 25th 2022

Addressing common misconceptions can help avoid misconstrued scientific facts

Mitigate diabetic retinopathy with early improved glucose control

Mitigate diabetic retinopathy with early improved glucose control

A. Paul Chous, MA, OD, FAAO
January 25th 2022

Timing is key in reducing the risk of developing vision loss or blindness.

RGX-314 clinical program: second pivotal trial to begin

RGX-314 clinical program: second pivotal trial to begin

Optometry Times Staff Reports
January 13th 2022

ASCENT, RegenXBio’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.

'Open Your Eyes' heads to premiere on Jan. 28

'Open Your Eyes' documentary to premiere this month

Optometry Times Staff Reports;Kerry Gelb, OD
January 2nd 2022

Exciting news from OYE Technology!

Optic disk swelling in an asymptomatic patient with diabetes

Optic disk swelling in an asymptomatic patient with diabetes

A. Paul Chous, MA, OD, FAAO
November 12th 2021

Diabetic papillitis is relatively rare, found in type 1 and 2 diabetes patients

COVID-19 triggers macrophage-mediated cytokine storm in diabetic patients

COVID-19 triggers macrophage-mediated cytokine storm in diabetic patients

Lynda Charters
October 27th 2021
Central serous retinopathy is not a benign disease

Central serous retinopathy is not a benign disease

Leo P. Semes, OD, FAAO
October 4th 2021

Remain vigilant to recurrences to apply potential treatments

ODs are ignoring macular degeneration

ODs are ignoring macular degeneration

Steven Ferrucci, OD, FAAO
September 15th 2021

Practitioners spend more time diagnosing glaucoma or diabetic retinopathy than AMD

Impact of sleep on diabetes and diabetic retinopathy

Impact of sleep on diabetes and diabetic retinopathy

A. Paul Chous, MA, OD, FAAO
August 19th 2021

Prescribed sleep hygiene may reduce the risk of severe eye disease and vision loss

How diabetes and glaucoma intersect

How diabetes and glaucoma intersect

David Yang, OD, FAAO;Lee Vien, OD, FAAO
August 11th 2021

Consider the impact of diabetes on management of patients with glaucoma

Embrace, don’t fear, AI in diabetic retinopathy

Embrace, don’t fear, AI in diabetic retinopathy

A. Paul Chous, MA, OD, FAAO
May 11th 2021

Automated detection of disease helps patients as well as doctors

How ODs can address patients lost to follow up

How ODs can address patients lost to follow up

A. Paul Chous, MA, OD, FAAO
January 4th 2021

Practitioners need to educate and stress the importance of additional care

How diabetes affects COVID-19

How diabetes affects COVID-19

A. Paul Chous, MA, OD, FAAO
November 12th 2020

Considerations for eyecare providers to better care for their patients with diabetes

Medical optometry and comprehensive eye care

Medical optometry and comprehensive eye care

Scott Schachter, OD
October 19th 2020

Eye physicals should be full-scope

Pipeline: Potential new therapy coming for macular disease

Pipeline: Potential new therapy coming for macular disease

Steven Ferrucci, OD, FAAO
October 9th 2020

Faricimab shows promise in treating diabetic macular edema and age-related macular degeneration

Patient education vs patient relations?

Patient education vs patient relations?

Mohammad Rafieetary, OD, FAAO
September 9th 2020

• Relatable patient education improves quality of care and prognosis • Although patients with moderate NPDR without DME can be followed every 6 to 9 months, when macular involvement is present patient needs more frequent follow-up • Patients with diabetic retinopathy need to be informed about importance of follow-up care even in the absence of their vision changes

Improve your detection rate of retinal neovascularization

Improve your detection rate of retinal neovascularization

Mohammad Rafieetary, OD, FAAO
September 9th 2020

If a complete examination is not possible in diabetic patients, pay close attention to the inferior retina.

12 lifestyle factors determine 40 percent of dementia cases

12 lifestyle factors determine 40 percent of dementia cases

Brooke Henson, Editor
August 19th 2020
Aflibercept PANORAMA study results in

Aflibercept PANORAMA study results in

A. Paul Chous, MA, OD, FAAO
August 13th 2020

Patients who switched to as-needed dosing experienced increased complications

Diabetic retinopathy treatment practical review

Diabetic retinopathy treatment practical review

Mohammad Rafieetary, OD, FAAO
August 5th 2020

When should ODs sends their patient to a retina specialist?

What causes vision loss in diabetic patients

What causes vision loss in diabetic patients

Mohammad Rafieetary, OD, FAAO
August 5th 2020

Vision loss caused by diabetic retinopathy comes in different packages.

Role of comorbidities in management of diabetic retinopathy

Role of comorbidities in management of diabetic retinopathy

Mohammad Rafieetary, OD, FAAO
July 7th 2020

ODs must pay close attention and manage all factors responsible for disease progression to improve the patient’s final outcome. The patient in this case report shows the importance of such management.

12345>
© 2023 MJH Life Sciences

All rights reserved.